Hims & Hers is preparing to enter the peptide market, and if you own a cash-pay practice, this is something worth paying attention to for reasons that have very little to do with whether you personally plan to prescribe peptides.

Reuters reported this month that Hims & Hers is preparing to launch legally available peptide therapies including NAD+, sermorelin and glutathione, while continuing to monitor the regulatory pathway around other compounds. The company has also been unusually vocal about peptide regulation, publicly supporting clearer FDA guidance and stating that it intends to build within whatever framework ultimately emerges. (Reuters)

What interests me is not that Hims & Hers wants to sell peptides. Of course they do. Peptides sit directly at the intersection of longevity, metabolic health, body composition, recovery and consumer interest, which are some of the fastest-moving categories in cash-pay medicine right now. What interests me is how early they are preparing for the category and how much infrastructure they already have around it.

This is the part independent practice owners tend to underestimate.

Hims & Hers did not wait until the GLP-1 market was mature to figure out how to sell weight loss. It built a consumer brand, acquisition engine, telehealth infrastructure, pharmacy relationships, recurring revenue model and patient experience capable of absorbing an enormous new category when consumer demand exploded. Now the company offers multiple FDA-approved GLP-1 options and pairs them with ongoing care and support. (Hims Newsroom)

Peptides are likely to follow a similar pattern. There will be a period where access itself feels special. Patients will search for the clinician in their area who knows about the newest therapy. Practices will build pages advertising individual compounds. Someone will make a peptide price sheet. Someone else will package three of them together and call it a longevity membership.

Then the market will mature.

Access will get easier. Consumers will become more educated. Large platforms will enter. Prices will become more transparent. The medications that currently feel exotic will start to feel increasingly ordinary.

That is when the difference between having a peptide service and having an actual business becomes very obvious.

If your competitive advantage is that you can prescribe something your patient cannot easily get elsewhere, your advantage has an expiration date.

A company like Hims & Hers can usually beat an independent practice on convenience. It can spend more on advertising. It can build better technology. It can remove more friction from onboarding. It can create an app that keeps a patient in continuous conversation with providers, care teams and AI, which is exactly what the company rolled out this month for Hers weight loss members. (Hims Newsroom)

Trying to compete with that by offering the same molecule for $50 less is not a particularly interesting business strategy.

The opportunity for independent practices is somewhere else entirely.

Your advantage is context.

You know the woman who walks into your practice because she is gaining weight at 47 despite doing the same things that worked at 37. You know she is sleeping five hours a night. You know her lean mass is declining. You know she is perimenopausal, her ApoB is elevated, her mother had osteoporosis, she is on a GLP-1 she does not want to stay on forever, and she is terrified that the next twenty years of her health are going to feel like a slow decline.

She does not need someone to sell her a peptide.

She needs someone who can make sense of the entire picture.

That is an entirely different product.

This is where I think a lot of private practices are still thinking too small. We keep organizing businesses around what we can prescribe instead of what we know how to solve. We build hormone clinics, GLP-1 clinics, IV clinics and peptide clinics, then act surprised when a national company makes the treatment easier or cheaper to obtain.

The medication should never be the most valuable intellectual property in your business.

Your method should be.

If I were building a peptide strategy inside a practice today, I would not start with a peptide menu. I would start with the outcomes the practice wants to become known for.

A female longevity program could incorporate hormone management, metabolic health, muscle preservation, bone health, sexual health, sleep and cardiovascular risk, with peptide therapy used when there is sufficient evidence, an appropriate clinical indication and a legal pathway to prescribe it.

A metabolic longevity program could be built around body composition, insulin resistance, visceral fat, muscle preservation and long-term weight maintenance. Depending on the patient, the therapeutic plan might involve a GLP-1, hormone therapy, nutrition, resistance training, sleep treatment or other interventions. A peptide may belong in that plan. It should not be the plan.

A recovery or performance program could focus on strength, sleep, recovery, body composition and healthy aging. A men’s longevity program could integrate testosterone management when appropriate with cardiovascular risk, metabolic health, sexual function, muscle and cognition. A post-GLP-1 program could address one of the next major clinical and commercial opportunities in this market: what happens after someone loses the weight.

Those are businesses that can survive changes in the therapeutic landscape.

A “sermorelin membership” is much more fragile.

The regulatory environment alone should make practices think this way. Hims & Hers has repeatedly framed its peptide plans around FDA-compliant pathways rather than assuming today’s access will look exactly like tomorrow’s. (Hims Newsroom) If a billion-dollar consumer health company is designing around regulatory uncertainty, an independent practice should probably do the same.

There is also a much better recurring revenue model hiding inside this.

Instead of putting a patient into an indefinite monthly medication membership on day one, I would separate optimization from maintenance. Most complex cash-pay patients require more clinical work at the beginning. They need a thorough assessment, appropriate diagnostics, interpretation, treatment planning, medication decisions, follow-up and adjustments. That is the intensive phase of care, and it should be priced and delivered accordingly.

Once the patient is stable, the relationship changes. They may need scheduled lab review, periodic body composition assessment, medication management, risk-factor surveillance, an annual deeper evaluation and access to their care team when something materially changes. That is where a continuity membership becomes incredibly valuable.

Now the patient is not paying $299 a month because a vial arrives at the door.

She is paying because someone is managing her longitudinal health strategy.

That distinction matters enormously.

It also creates a much stronger business. When your revenue depends on a specific medication, every regulatory change, shortage, manufacturer price cut or telehealth competitor becomes a threat. When your revenue is attached to an outcome and a relationship, the therapeutic tools underneath the program can change without destroying the offer.

That is the direction I believe cash-pay medicine is moving.

The practices that win the next decade will not necessarily be the ones that introduce every new therapy first. They will be the ones that know how to absorb new therapies into a coherent clinical model without allowing the therapy to become the business.

Hims & Hers appears to understand this very well. Its peptide interest sits inside a much broader push into longevity, hormonal health, labs, proactive care and technology. When the company hired Anant Vinjamoori as chief medical officer of Hims earlier this summer, it explicitly identified longevity medicine and peptide therapy as emerging categories alongside established areas such as hormone health, sexual health, dermatology and weight loss. (Hims Newsroom)

That is not the behavior of a company adding another service line.

It is the behavior of a company deciding where healthcare consumer demand is going next and building the operating system required to capture it.

Independent practices should be thinking the same way.

Not because you need to become Hims & Hers.

You should not.

Your advantage is precisely that you are not a mass-market telehealth company.

You can offer depth, specialization, clinical judgment and a level of longitudinal context that is much more difficult to reproduce at scale. But that advantage only matters if you build a business model around it.

This is the work we are focused on at TAP: helping practices turn clinical expertise into offers, patient journeys, systems and continuity models that remain valuable even as medicine changes around them.

Because peptides will not be the last category to arrive.

There will always be another drug, diagnostic, device or intervention that everyone suddenly wants.

The goal is not to build your practice around the next thing.

It is to build a practice capable of monetizing the next thing without becoming dependent on it.

Hims & Hers is preparing for the peptide market.

The better question is whether your business is prepared for what happens after peptides become mainstream.